1668 / 1778
EMBRACE-II interventions – tumour control
•
Increased use of IC/IS BT
–
CTV-HR >30cc, >70%
•
Adaptation of EBRT nodal elective CTV according to risk of
nodal and systemic recurrence
•
Systematic application of simultaneous chemotherapy
•
Reduction of overall treatment time (≤ 50 days)